Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Olaparib's Real-World impact on prostate cancer

NCT ID NCT06031805

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 300 men with metastatic castration-resistant prostate cancer who are taking olaparib in everyday medical practice. Researchers will track how long patients stay on the drug, how well it controls the cancer, and any side effects. The goal is to learn how olaparib is used in the real world to improve future treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult male patients with metastatic castration-resistant prostate cancer who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program A sample of approximately 300 patients is expected to be enrolled from around 60 french sites.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Adult male patients (≥ 18 years old) * with metastatic castration-resistant prostate cancer, * who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program * who have been informed and are not opposed to their data collection --- For Patients initiated with olaparib in fEA, * Still alive and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician); * who deceased and who did not object to data collection for research purpose(s) during his or her lifetime. Exclusion criteria * Patients opposed to the collection of their data * Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic castration resistant prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic castration resistant prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    63 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Amiens, France

  • Research Site

    NOT_YET_RECRUITING

    Angers, France

  • Research Site

    RECRUITING

    Antony, France

  • Research Site

    RECRUITING

    Argenteuil, France

  • Research Site

    RECRUITING

    Avignon, France

  • Research Site

    NOT_YET_RECRUITING

    Avignon, France

  • Research Site

    RECRUITING

    Besançon, France

  • Research Site

    NOT_YET_RECRUITING

    Bordeaux, France

  • Research Site

    RECRUITING

    Bordeaux, France

  • Research Site

    WITHDRAWN

    Bordeaux, France

  • Research Site

    RECRUITING

    Challes-les-Eaux, France

  • Research Site

    RECRUITING

    Chambray-lès-Tours, France

  • Research Site

    NOT_YET_RECRUITING

    Chambray-lès-Tours, France

  • Research Site

    NOT_YET_RECRUITING

    Champigny-sur-Marne, France

  • Research Site

    RECRUITING

    Clermont-Ferrand, France

  • Research Site

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • Research Site

    RECRUITING

    Compiègne, France

  • Research Site

    RECRUITING

    Créteil, France

  • Research Site

    RECRUITING

    Epagny METZ Tessy, France

  • Research Site

    NOT_YET_RECRUITING

    Epagny METZ Tessy, France

  • Research Site

    RECRUITING

    Ermont, France

  • Research Site

    RECRUITING

    FORT de France, France

  • Research Site

    RECRUITING

    Fréjus, France

  • Research Site

    NOT_YET_RECRUITING

    Fréjus, France

  • Research Site

    RECRUITING

    Grenoble, France

  • Research Site

    NOT_YET_RECRUITING

    Le Chesnay, France

  • Research Site

    RECRUITING

    Le Coudray, France

  • Research Site

    NOT_YET_RECRUITING

    Le Coudray, France

  • Research Site

    NOT_YET_RECRUITING

    Le Mans, France

  • Research Site

    RECRUITING

    Levallois-Perret, France

  • Research Site

    RECRUITING

    Lyon, France

  • Research Site

    NOT_YET_RECRUITING

    Lyon, France

  • Research Site

    RECRUITING

    Mantes-la-Jolie, France

  • Research Site

    NOT_YET_RECRUITING

    Mantes-la-Jolie, France

  • Research Site

    NOT_YET_RECRUITING

    Marseille, France

  • Research Site

    NOT_YET_RECRUITING

    Morlaix, France

  • Research Site

    RECRUITING

    Nancy, France

  • Research Site

    NOT_YET_RECRUITING

    Nancy, France

  • Research Site

    RECRUITING

    Nantes, France

  • Research Site

    RECRUITING

    Nice, France

  • Research Site

    RECRUITING

    ORL ANS, France

  • Research Site

    RECRUITING

    Paris, France

  • Research Site

    NOT_YET_RECRUITING

    Paris, France

  • Research Site

    RECRUITING

    Pointe à Pitre, France

  • Research Site

    RECRUITING

    Poitiers, France

  • Research Site

    RECRUITING

    Pontoise, France

  • Research Site

    NOT_YET_RECRUITING

    Quint-Fonsegrives, France

  • Research Site

    RECRUITING

    Rouen, France

  • Research Site

    NOT_YET_RECRUITING

    Rouen, France

  • Research Site

    NOT_YET_RECRUITING

    Saint Denis- LA Reunion, France

  • Research Site

    NOT_YET_RECRUITING

    Saint-Doulchard, France

  • Research Site

    RECRUITING

    Saint-Etienne, France

  • Research Site

    NOT_YET_RECRUITING

    Saint-Etienne, France

  • Research Site

    RECRUITING

    Saint-Grégoire, France

  • Research Site

    WITHDRAWN

    Saint-Grégoire, France

  • Research Site

    RECRUITING

    Saint-Mandé, France

  • Research Site

    RECRUITING

    Saint-Nazaire, France

  • Research Site

    NOT_YET_RECRUITING

    Saint-Nazaire, France

  • Research Site

    RECRUITING

    Strasbourg, France

  • Research Site

    NOT_YET_RECRUITING

    Suresnes, France

  • Research Site

    RECRUITING

    Tours, France

  • Research Site

    NOT_YET_RECRUITING

    Vannes, France

  • Research Site

    RECRUITING

    Vannes, France

  • Research Site

    RECRUITING

    Vantoux, France

  • Research Site

    NOT_YET_RECRUITING

    Vantoux, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.